Source: PR Newswire

Press Release: Gritstone Bio : Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS) of a class action securities...

Read full article »

Gritstone Bio's Competitors | Gritstone Bio's News | Gritstone Bio's Financials

Followers on Owler

229

Annual Revenue

$5.0-25M

Employees

100-250

President & CEO

Andrew Allen

CEO Approval Rating

90/100

Gritstone Bio is a California-based biotechnology company that develops and commercializes immunotherapies for the treatment of cancer and infectious diseases.